Nektar Therapeutics Inc (NKTR)

13.28
NASDAQ : Health Care
Prev Close 12.95
Day Low/High 12.98 / 13.40
52 Wk Low/High 10.52 / 19.98
Avg Volume 1.86M
Exchange NASDAQ
Shares Outstanding 152.84M
Market Cap 1.98B
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Nektar To Hold Investor & Analyst Event At 2016 Society For Immunotherapy Of Cancer Annual Meeting

Nektar To Hold Investor & Analyst Event At 2016 Society For Immunotherapy Of Cancer Annual Meeting

Data from Phase 1 dose-escalation trial of NKTR-214 to be presented by lead clinical investigators

Nektar Therapeutics Announces Upcoming Presentations At The 2016 Society For Immunotherapy Of Cancer Annual Meeting

Nektar Therapeutics Announces Upcoming Presentations At The 2016 Society For Immunotherapy Of Cancer Annual Meeting

Five data presentations will showcase Nektar's immuno-oncology candidates, NKTR-214 and NKTR-255

Short Interest Jumps 12.5% For NKTR

Short Interest Jumps 12.5% For NKTR

The most recent short interest data has been released for the 10/14/2016 settlement date, which shows a 1,041,247 share increase in total short interest for Nektar Therapeutics , to 9,398,731, an increase of 12.46% since 09/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Schlumberger, Amazon, Apple: Doug Kass' Views

Schlumberger, Amazon, Apple: Doug Kass' Views

Doug Kass shares his thoughts on 'stuck' markets and on differing risk appetites and timeframes.

Nektar Therapeutics (NKTR) Stock Falls on Public Offering Pricing

Nektar Therapeutics (NKTR) Stock Falls on Public Offering Pricing

Nektar Therapeutics (NKTR) said on Wednesday that it would sell 13 million shares of common stock at $13.50 each.

Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy

Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy

A series of clinical trials will test the combination of Bristol-Myers Squibb's Opdivo with Nektar's NKTR-214 in multiple tumor types.

Bristol-Myers Squibb And Nektar Therapeutics Announce Oncology Clinical Collaboration To Evaluate The Combination Of Opdivo (nivolumab) And NKTR-214

Bristol-Myers Squibb And Nektar Therapeutics Announce Oncology Clinical Collaboration To Evaluate The Combination Of Opdivo (nivolumab) And NKTR-214

Bristol-Myers Squibb Company (NYSE:BMY) and Nektar Therapeutics (Nasdaq:NKTR) today announced a new clinical collaboration to evaluate Bristol-Myers Squibb's Opdivo (nivolumab) with Nektar's investigational...

Here's Why Investors Should Steer Clear of Opioids

Here's Why Investors Should Steer Clear of Opioids

Backed by the government, initiatives to develop and popularize non-opioid painkillers can make investors high on profits.

4 Biotech Stock Charts You Must See

4 Biotech Stock Charts You Must See

Biotech stocks dominate our list of top charts today. Here are four to watch.

Rev's Forum: Let's See If Bulls Can Sustain Friday's Momentum

Rev's Forum: Let's See If Bulls Can Sustain Friday's Momentum

The big issue is if the market can build on Friday's jobs good news.

Don't Roll the Dice on Central Bank News

Don't Roll the Dice on Central Bank News

The bears are trying it out on the Bank of England news today, but they may get squeezed.

Using My Metal Detector Amid Gold and Silver Strength

Using My Metal Detector Amid Gold and Silver Strength

Computer programming has found that buying bad-news dips is a consistent winner.

Nektar Therapeutics (NKTR) Flagged As Strong On High Volume

Nektar Therapeutics (NKTR) Flagged As Strong On High Volume

Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a strong on high relative volume candidate

Nektar Therapeutics Announces Executive Management Promotions

Nektar Therapeutics Announces Executive Management Promotions

John Nicholson named Senior Vice President & Chief Operating Officer of Nektar; Gil M. Labrucherie named Senior Vice President & Chief Financial Officer of Nektar

Nektar Therapeutics (NKTR) Weak On High Volume Today

Nektar Therapeutics (NKTR) Weak On High Volume Today

Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a weak on high relative volume candidate

Facebook, Ford and General Motors: Doug Kass' Views

Facebook, Ford and General Motors: Doug Kass' Views

Doug Kass shares his thoughts on two auto stocks and Facebook.

Novice Trade: Nektar Therapeutics

Plus an update on the Urban Outfitters trade from yesterday.